The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1250 Weight Loss articles
Two-thirds of South Korea's GLP-1 obesity drugs, including Wegovy and Mounjaro, flow to Greater Seoul despite higher obesity rates elsewhere. This supply imbalance raises alarms over access for high-risk patients. Data reveals stark regional disparities in distribution.
GLP-1 drugs like Ozempic and Mounjaro have revolutionized weight loss, and the next wave—GLP-3s such as retatrutide—promises even greater results. Eli Lilly's phase 3 trial revealed up to 28.7% body weight loss in 48 weeks. Discover monthly injections, oral pills, and emerging indications for 2026.
A woman called Mounjaro 'magical' after dropping 3.5 stone and easing PCOS symptoms. But intense pain hospitalized her with pancreatitis linked to the drug. Now facing lifelong risks, she warns others to monitor symptoms closely.
Alisha Trafford called Mounjaro 'magical' after dropping 3.5 stone and easing PCOS symptoms. But intense pain led to hospitalizations for pancreatitis and pancreatic necrosis, linked by doctors to the drug. She warns others to monitor symptoms closely.
GLP-1 receptor agonists excel in weight management and glucose control, but their effects on women's reproductive health demand attention. These drugs can restore ovulation in obese women with insulin resistance, yet they risk unplanned pregnancies and are unsafe during gestation. Consult experts before use.
GLP-1 weight loss drugs like Ozempic may trim airline fuel bills alongside waistlines. A Jefferies report estimates $580M annual savings for top US carriers from lighter passengers. Discover the science and implications.
Popular GLP-1 drugs are delivering unexpected savings to airlines, with $580 million in annual fuel cost reductions projected for major U.S. carriers. Analyst Sheila Kahyaoglu's research links passenger weight loss to lower operating expenses. Discover how this weight management trend reshapes aviation economics.
Doctor Karan Rajan explains why you might regain weight after quitting GLP-1 drugs: they mimic treatments for chronic conditions like high blood pressure. Obesity requires ongoing management with lifestyle factors like diet, exercise, and sleep. Not everyone needs GLP-1s forever, but stopping without changes risks relapse.
One-third of South Africans live with obesity, driving new clinical guidelines that endorse GLP-1 drugs like Ozempic, Mounjaro, and Wegovy. These medications lower blood sugar, slow digestion, and promote fullness but face affordability barriers. Experts urge political action for broader access.
